SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and outlook dominate discussion, with traders focused on subscriber engagement and growth, ad revenue, and the effect of recent layoffs and content-leadership changes. Views are sharply divided: some see low expectations and a chance for a rebound, while others fear further weakness, citing the stocks decline and its recent post-earnings performance.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plan to pursue a public listing for its Monee financial-services arm is fueling debate as shares sell off. Some traders see the separation and uncertain timeline as an overhang that could leave Sea with less valuable businesses, while others argue shareholders could benefit from receiving Monee shares or from the business being valued separately.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Speculation around a potential buyoutfueled by the CEOs anniversary message and the companys planned ASH presenceis competing with anticipation of a final analysis of SELLASs REGAL Phase 3 trial, last reported at 78 of 80 required events. Some traders read the prolonged trial and managements upbeat tone as encouraging, while others stress that no acquisition, event threshold, or trial result has been confirmed and that the recent price move may be trading without fresh news.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance despite growth in its commercial business, with many traders blaming weak confidence in management and the companys acquisition-focused strategy. The debate centers on debt and dilution concerns versus the potential of upcoming Navenibart and Netherton data to support the pipeline and restore confidence.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp has driven a sharp rally, with traders focused on the cash proceeds and potential balance-sheet and strategic benefits. The reaction is divided: some see a positive reset, while skeptics worry the divestiture removes a meaningful revenue business and leaves weaker operations and debt concerns.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is selling off despite a quarterly earnings beat and higher full-year guidance, as traders focus on rising costs, weaker cash conversion, lower-margin sales and a loss in its insurance business; some also worry that engines are accumulating at Boeing ahead of aircraft deliveries. The reaction has frustrated bullish traders who see strong demand and orders, while others view the selloff as evidence that profitability and execution matter more than the headline beat.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta is drawing attention as shares rebound while traders look ahead to clinical readouts for its DM1 and FSHD siRNA programs, alongside discussion of Arrowhead data as a possible validation of the technology. Bulls see the pipeline as a potential growth driver, while skeptics say early or preclinical results still need to translate into meaningful patient benefit and question the stocks weak price action.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being discussed alongside expectations of Republican losses in the midterms and declining confidence in Trump, with many traders blaming the stocks political association and questioning the companys business value. The conversation is predominantly bearish, though some traders see a possible short-term bounce.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat, improved medical-cost ratio and raised full-year outlook are driving attention, with traders framing the results as evidence of a turnaround. The initial post-earnings gains faded, prompting debate over whether margin recovery is durable or whether lingering cost and Medicare Advantage concerns will continue to weigh on the stock.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat was overshadowed by a narrowed full-year profit outlook with an unchanged midpoint, prompting a sharp selloff despite a higher free-cash-flow outlook and a new share-buyback authorization. Traders are split between viewing the drop as a buying opportunity given cash generation and buybacks, and seeing the guidance as a sign of weaker prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’

Equity

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.


BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 


Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately. 

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

Bullish Sentiment

<ul class="summary-bullets"><li>RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform,’ according to The Fly.</li><li>BioCryst expects revenue from Orladeyo between $625 million and $645 million in full-year 2026.</li><li>The brokerage sees longer-term potential from BioCryst’s second HAE drug, Navenibart.</li></ul>BioCryst Pharmaceuticals (BCRX) was in the spotlight on Thursday, after RBC Capital said the biotech firm faces a “challenging near-term outlook” after Pharvaris (PHVS) published strong late-stage data for hereditary angioedema (HAE) therapy.RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform’ and lowered the price target to $11 from $13, according to The Fly. BCRX shares are currently trading near $8.The firm said Pharvaris’ experimental therapy could pressure its key hereditary angioedema drug, Orladeyo, and expects the shares to remain range-bound until new catalysts emerge.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/BCRX">BCRX shares</a> were down 8%, heading for their fifth straight session of losses.&nbsp;The stock has already shed more than 20% of its value so far over the five sessions.<h2 class="st-heading-2">Pharvaris Data Raises Competition</h2>The downgrade follows Phase 3 results for Pharvaris’ Deucrictibant XR, an experimental once-daily pill designed to prevent HAE attacks. HAE is a rare genetic condition that causes episodes of swelling in different parts of a child’s body, including the face, hands, and feet.Pharvaris said the drug reduced monthly attacks by 83% compared with placebo in its Chapter-3 study. The drug was generally well tolerated, and the company plans to begin seeking regulatory approvals in the first half of 2027.<h2 class="st-heading-2">RBC Expects Revenue Tailwinds For Orladeyo</h2>RBC believes the results could lead patients to switch away from Orladeyo and reduce the drug’s longer-term revenue to about $400 million to $450 million.The drug generated sales of over $600 million in full-year 2025, and the company expects revenue of $625 million to $645 million in 2026.Still, RBC sees longer-term potential from BioCryst’s second HAE drug, Navenibart. The Phase 3 study is fully enrolled, with six- and 12-month efficacy data expected in the third quarter of 2027.<h2 class="st-heading-2">Retail’s Take On BCRX</h2>Retail sentiment surrounding BCRX on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.One user opined that the “execution risk just rose for Navenibart.”<stembedurl>https://stocktwits.com/Cap_00/message/663973370</stembedurl>The stock has gained around 4% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/brent-futures-top-105-per-barrel-as-houthis-seize-strategic-red-sea-port-opec-cuts-2026-demand-outlook/cZtagdoRJ62">&nbsp;Brent Futures Top $105 Per Barrel As Houthis Seize Strategic Red Sea Port — OPEC Cuts 2026 Demand Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

Sentiment is heavily polarized on the upcoming Navenibart data, with traders debating whether success will trigger a major rerating or failure confirms terminal decline.

Traders are closely watching unexplained spikes in daily block volume ahead of November earnings, fueling speculation about potential positioning.

Current Price	$7.88
Prev Close	$8.07
Open	$8.08
Dividend Yield	0.00%
50-Day Moving Average	$8.98
Beta	0.98
Avg. Volume	5.47M
PE Ratio	-5.37

52-Week High	$11.22
52-Week Low	$6.23
Market Capitalization	$2.06B
EPS (Annual)	$1.21
Price to Book	-4.53
Revenue Per Employee	$2.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRX Fundamentals